Drug Profile
Research programme: alkylatlng histone deacetylase inhibitors - Mundipharma EDO
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Northlake International
- Developer Mundipharma EDO
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in Switzerland
- 28 Jul 2018 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland
- 27 Nov 2012 Early research Haematological malignancies in United Kingdom (unspecified route)